Co-Targeting of the PI3K and RAS Pathways for the Treatment of Carcinoid Tumors

被引：0
|
作者：
Valentino, Joseph
Li, Jing
Kim, Ji Tae
Song, Jun
Mustain, W. C.
Weiss, Heidi L.
Anthony, Lowell
Townsend, Courtney M.
Evers, B. Mark
机构：
来源：
GASTROENTEROLOGY | 2012年 / 142卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S644 / S644
页数：1
相关论文
共 50 条
  • [1] Co-targeting PI3K and ras pathways in trastuzumab resistance.
    Gray, Mike J.
    YangKolodji, Gloria Wangrong
    Tripathy, Debu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
    Valentino, Joseph D.
    Li, Jing
    Zaytseva, Yekaterina Y.
    Mustain, W. Conan
    Elliott, Victoria A.
    Kim, Ji Tae
    Harris, Jennifer W.
    Campbell, Katherine
    Weiss, Heidi
    Wang, Chi
    Song, Jun
    Anthony, Lowell
    Townsend, Courtney M., Jr.
    Evers, B. Mark
    CLINICAL CANCER RESEARCH, 2014, 20 (05) : 1212 - 1222
  • [3] Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
    Moore, Gillian
    Lightner, Clara
    Elbai, Samira
    Brady, Lauren
    Nicholson, Siobhan
    Ryan, Ronan
    O'Sullivan, Katie E.
    O'Byrne, Kenneth J.
    Blanco-Aparicio, Carmen
    Cuffe, Sinead
    O'Neill, Michael
    Heavey, Susan
    Finn, Stephen P.
    Gately, Kathy
    CANCERS, 2021, 13 (09)
  • [4] Co-targeting the PI3K and androgen receptor signal pathways in castration resistant prostate cancer
    De Velasco, Marco A.
    Kura, Yurie
    Ando, Naomi
    Fukushima, Emiko
    Hatanaka, Yuji
    Yamamoto, Yutaka
    Shimizu, Nobutaka
    Yoshimura, Kazuhiro
    Nozawa, Masahiro
    Yoshikawa, Kazuhiro
    Nishio, Kazuto
    Uemura, Hirotsugu
    CANCER RESEARCH, 2014, 74 (19)
  • [5] CO-TARGETING THE PI3K-MTOR & MEK PATHWAYS IN NSCLC
    Heavey, S.
    Barr, M.
    Ahmad, A.
    Davies, A.
    O'Byrne, K. J.
    Gately, K. A.
    ANNALS OF ONCOLOGY, 2012, 23 : 69 - 70
  • [6] Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC
    Heavey, Susan
    O'Byrne, Kenneth J.
    Gately, Kathy
    CANCER TREATMENT REVIEWS, 2014, 40 (03) : 445 - 456
  • [7] Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors.
    Blanco Aparicio, Carmen
    Renner, Oliver
    Gomez-Casero, Elena
    Cebria, Antonio
    Ajenjo, Nuria
    Aguirre, Enara
    Cebrian, David
    Rodriguez de Miguel, Ma Carmen
    Pequeno, Belen
    Isabel Albarran, Ma
    Riesco, Rosario
    Belen Garcia, Ana
    Alvarez, Rosa
    O'Neill, Michael
    Martinez, Sonia
    Pastor, Joaquin
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [8] Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways
    Lackner, Mark R.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2010, 10 (01) : 75 - 87
  • [9] Improvement of radiotherapy for glioblastoma by co-targeting PI3K and HSP90
    Wachsberger, Phyllis Rachelle
    Lawrence, Richard Y.
    Liu, Yi
    Andersen, Barbara
    Dicker, Adam P.
    CANCER RESEARCH, 2012, 72
  • [10] Co-targeting the PI3K and MEK pathways in NSCLC: an in vitro evaluation and mutation prevalence in an Irish patient cohort
    Heavey, S.
    Barr, M. P.
    Hennessy, B.
    Toomey, S.
    Carr, A.
    Crown, J.
    Finn, S.
    Cuffe, S.
    O'Byrne, K. J.
    Gately, K. A.
    LUNG CANCER, 2014, 83 : S4 - S4
12345